News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

New Study Published in JAMA Supports Neurotez, Inc. Plans for the Development of Leptin as a Therapy for AD



12/17/2009 9:53:13 AM

Bookmark and Share

BRIDGEWATER, N.J.--(BUSINESS WIRE)--This week’s issue of the Journal of the American Medical Association (Dec 16) features a report on a long-term, prospective study of elderly, dementia-free individuals led by researchers from Boston University School of Medicine and the Framingham Heart Study focusing on the association between the protein hormone Leptin and the risk of developing Alzheimer’s disease (AD). Specifically, people with higher baseline circulating Leptin levels were found to have a significantly reduced incidence of AD and dementia. Individuals in the lowest quartile of gender-specific Leptin levels had an absolute AD risk of 25%, while persons in the highest quartile had only a 6% risk over a 12-year follow-up period.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES